Purpose:

To review the electropharmacology, clinical applications, side effects, and hemodynamic profile of intravenous amiodarone.

Data Sources:

The MEDLINE database was searched for English-language material, including reports of clinical trials and in vivo studies, review articles, and abstracts presented at national symposia, that was published between 1985 and 1996. Bibliographies of textbooks and articles were also examined.

Study Selection:

Studies that reported on the efficacy, toxicity, and hemodynamic profile of intravenous amiodarone and studies that examined the pharmacologic behavior of intravenous amiodarone in laboratory models were reviewed.

Data Extraction:

Study design and quality and relevant data on efficacy of suppression and treatment of arrhythmias with oral and intravenous amiodarone therapy, the reported mechanisms of antiarrhythmic effect, and hemodynamic changes seen with therapy were analyzed.

Data Synthesis:

Amiodarone is a unique antiarrhythmic agent that is now available in oral and intravenous forms in the United States. The use of intravenous amiodarone in the short-term treatment of life-threatening or hemodynamically unstable rhythm disturbances has generated much interest. Amiodarone has many electropharmacologic actions, some of which differ between the oral and intravenous forms. The wide clinical application of amiodarone includes treatment and prevention of supraventricular and ventricular arrhythmias and arrhythmias related to myocardial infarction. Intravenous amiodarone is effective for supraventricular and ventricular arrhythmias that are resistant to other antiarrhythmic agents. The effectiveness of intravenous amiodarone as short-term treatment also suggests that the drug has an important role in protocols of advanced cardiac life support. Intravenous amiodarone seems to have an overall favorable hemodynamic profile and does not produce many of the unwanted long-term side effects associated with oral therapy.

Conclusion:

Intravenous amiodarone shows much promise for the short-term treatment of unstable arrhythmias. Its favorable hemodynamic effects and minimal short-term side effects make it an attractive option in the management of cardiac arrhythmias.

References

  • 1. Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW. The Cardiac Arrhythmia Suppression Trial: first CAST … then CAST II. J Am Coll Carciol. 1992; 19:894-8 Google Scholar
  • 2. Podrid PJ. Amiodarone: reevaluation o4 an old drug Ann Intern Med. 1995; 122:689-700. Google Scholar
  • 3. The Medical Letter on Drugs and Therapeutics. 1995; 37:114-5. Google Scholar
  • 4. Hohnloser SH, Zabel M, Zehender M, Meinertz T, Just H. Efficacy of intravenously administered amiodarone for short-term control of serious arrhythmias. J Cardiovasc Pharmacol. 1992; 20:S63-9. Google Scholar
  • 5. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R. The historical development, cellular electrophysiology, and pharmacology of amiodarone. Prog Cardovasc D.s. 1989; 31:249-80. Google Scholar
  • 6. Singh BN, Nademanee K. Amiodarone and thyroid function: clirical implications during antiarrhythmic therapy. Am Heart J. 1983; 106:857-69. Google Scholar
  • 7. Talajic M, DeRoode R, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation. 1987; 75:265-7. Google Scholar
  • 8. Nattel S, Talajic M, Quantz M, DeRoode M. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. Circulation. 1987; 76 442-9. Google Scholar
  • 9. Wellens HJ, Brugada P, Abdollah H, Dassen WR. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation. 1984; 69:120-4. Google Scholar
  • 10. Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J. 1984; 108:890-8. Google Scholar
  • 11. Morady F, DiCarlo LA Jr, Krol RB, Baerman JM, de Buitleir MB. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol. 1986; 7:148-56. Google Scholar
  • 12. Mitchell LB, Wyse DG, Gillis AM, Duff HJ. Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. Circulation. 1989; 80:34-42. Google Scholar
  • 13. Kadish AH, Chen RF, Schmaltz S, Morady F. Magnitude and time course of β-adrenergic antagonism during oral amiodarone therapy. J Am Coll Cardiol. 1990; 16:1240-5. Google Scholar
  • 14. Roden DM. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol. 1993; 72:45F-50F. Google Scholar
  • 15. Polster P, Broekhuysen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol. 1976; 25:131-4. Google Scholar
  • 16. Connolly SJ, Latini R, Kates RE. Pharmacodynamics of intravenous amiodarone in the dog. J Cardiovasc Pharmacol. 1984; 6:531-5. Google Scholar
  • 17. Yabek SM, Kato R, Singh BN. Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Caroiovasc Pharmacol. 1986; 8:197-207. Google Scholar
  • 18. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J. 1983; 106:788-97. Google Scholar
  • 19. Kadish A, Morady F. The use of intravenous amiodarone in the acute therapy of life-threatening tachyarrhythmias. Prog Cardiovasc Dis. 1989; 31:281-94. Google Scholar
  • 20. Mayuga RD, Singer DH. Effects of intravenous amiodarone on electrical dispersion in normal and ischaemic tissues and on arrhythmia inducibility: monophasic action potential studies. Cardiovasc Res. 1992; 20:571-9. Google Scholar
  • 21. Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res. 1984; 55:277-87. Google Scholar
  • 22. Kojima S, Wu ST, Wikman-Coffelt J, Parmley WW. Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts. J Pharmacol Exp Ther. 1995; 275:254-62. Google Scholar
  • 23. Du XJ, Elser MD, Dart AM. Sympatholytic action of intravenous amiodarone in the rat heart. Circulation. 1995; 91:462-70. Google Scholar
  • 24. Naccarelli GV, Jalal S. Intravenous amiodarone. Another option in the acute management of sustained ventricular tachyarrhythmias [Editorial]. Circulation. 1995; 92:3154-55. Google Scholar
  • 25. Vitolo E, Tronci M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol. 1981; 36:431-44. Google Scholar
  • 26. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J. 1983; 106(4 pt 2):870-6. Google Scholar
  • 27. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol. 1986; 57:124-7. Google Scholar
  • 28. Horowitz LN, Speilman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol. 1985; 6:1402-7. Google Scholar
  • 29. Blevins RD, Kerin NZ, Benaderet D, Frumin H, Jarandilla R, Rubenfire M. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med. 1987; 147:1401-4. Google Scholar
  • 30. Brodsky MA, Allen BJ, Walker CJ 3d, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol. 1987; 60:572-5. Google Scholar
  • 31. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation and flutter. JAMA. 1991; 267:3289-93. Google Scholar
  • 32. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 1995; 76:47-50. Google Scholar
  • 33. Boriani G, Capucci A, Botto GL, Rubino I, Lenzi T, Ongari M, et al. Different pharmacologic treatment for converting recent-onset atrial fibrillation; evaluation on 377 patients. [Abstract]. J Am Coll Cardiol. 1996; 27(Suppl A):80A. Google Scholar
  • 34. Hohnloser SH, Meinertz T, Dammbacher T, Steiert K, Jahnchen E, Zehender M, et al. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J. 1991; 121:89-94. Google Scholar
  • 35. Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med. 1996; 156:49-63. Google Scholar
  • 36. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995; 75:693-7. Google Scholar
  • 37. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992; 70:69-72. Google Scholar
  • 38. Horner SM. A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion. Acta Cardiol. 1992; 47:473-80. Google Scholar
  • 39. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995; 16:521-8. Google Scholar
  • 40. Vietti-Ramus G, Veglio F, Marchisio U, Burzio P, Latini R. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. Int J Cardiol. 1992; 35:77-85. Google Scholar
  • 41. Chapman MJ, Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DN. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Med. 1993; 19:48-52. Google Scholar
  • 42. Zehender M, Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardioi. 1992; 19:1054-9. Google Scholar
  • 43. Negrini M, Gibelli G, DePonti C. Propafenone compared with amiodarone for conversion of paroxysmal atrial fibrillation to sinus rhythm [Abstract]. J Am Coll Cardiol. 1991; 17:131A. Google Scholar
  • 44. Sagrista-Sauleda J, Permanyer-Miralda G, Soler-Soler J. Electrical cardioversion after amiodarone administration. Am Heart J. 1992; 123:1536-42. Google Scholar
  • 45. Cybulski J, Kulakowski P, Makowska E, Czepiel A, Sikora-Frac M, Ceremuzynski L. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Clin Cardiol. 1996; 19:563-6. Google Scholar
  • 46. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras SM, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med. 1995; 23:1816-24. Google Scholar
  • 47. Horowitz LN, Mattleman SJ, Spielamm ST. Intravenous amiodarone loading for ventricular tachycardia [Abstract]. Circulation. 1982; 66:222. Google Scholar
  • 48. Morady F, Scheinman MM, Shen E, Shapiro W, Sung RJ, DiCarlo L. Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia. Am J Cardiol. 1983; 51:156-9. Google Scholar
  • 49. Saksena S, Rothbart ST, Shah Y, Cappello G. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. Am J Cardiol. 1984; 54:347-52. Google Scholar
  • 50. Klein RC, Machell C, Rushforth N, Standefur J. Efficacy of intravenous amiodarone as short-term treatment for refractory ventricular tachycardia. Am Heart J. 1988; 115:96-101. Google Scholar
  • 51. Drexler H, Meinertz T, Zeiher A, Kasper W, Just H. Wirksamkeit von Amiodaron iv in der Akutphase lidocainrefraktarer ventrikularer Tachykardien. Intensivemed. 1986; 23:179-82. Google Scholar
  • 52. Ochi RP, Goldenberg IF, Almquist A, Pritzker M, Milstein S, Pedersen W, et al. Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery disease. Am J Cardiol. 1989; 64:599-603. Google Scholar
  • 53. Mooss AN, Mohiuddin SM, Hee TT, Esterbrooks DJ, Hillerman DE, Rovang KS, et al. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. Am J Cardiol. 1990; 65:609-14. Google Scholar
  • 54. Schutzenberger W, Leisch F, Kerschner K, Harringer W, Herbinger W. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Br Heart J. 1989; 62:367-71. Google Scholar
  • 55. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995; 92:3264-72. Google Scholar
  • 56. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995; 92:3255-63. Google Scholar
  • 57. Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol. 1996; 27:67-75. Google Scholar
  • 58. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990; 16:1711-8. Google Scholar
  • 59. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation. 1991; 84:550-7. Google Scholar
  • 60. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol. 1992; 20:1056-62. Google Scholar
  • 61. Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders; 1992:1239-49. Google Scholar
  • 62. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27:335-71. Google Scholar
  • 63. Norris RM, Barnaby PF, Brown MA, Geary GG, Clarke ED, Logan RL, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propanolol. Lancet. 1984; 2:883-6. Google Scholar
  • 64. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991; 83:422-7. Google Scholar
  • 65. Remme WJ, Kruyssen HA, Look MP, van Hoogenhuyze DC, Krauss XH. Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. Am Heart J. 1991; 122:96-103. Google Scholar
  • 66. Twidale N, Roberts-Thomson P, McRitchie RJ. Comparative hemodynamic effects of amiodarone, sotalol, and D-sotalol. Am Heart J. 1992; 126:122-9. Google Scholar
  • 67. Anastasiou-Nana MI, Nanas JN, Nanas SN, Rapti A, Poyadijs A, Stathaki S, et al. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experemental study. J Am Coll Cardiol. 1994; 23:253-8. Google Scholar
  • 68. Nalos PC, Ismail Y, Pappas JM, Nyitray W, DonMichael TN. Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. Am Heart J. 1991; 122:1629-32. Google Scholar
  • 69. Williams ML, Woelfel A, Cascio WE, Simpson RJ Jr, Gettes LS, Foster JR. Intravenous amiodarone during prolonged resuscitation from cardiac arrest. Ann intern Med. 1989; 110:839-42. Google Scholar
  • 70. Bedell SE, Delbanco TL, Cook EF, Epstein FH. Survival after cardiopulmonary resuscitation in the hospital. N Engl J Med. 1983; 309:569-76. Google Scholar
  • 71. Physicians' Desk Reference. 49th ed. Montvale, NJ: Medical Economics Data; 1995:2659. Google Scholar